TSK OptiXion
Tsk Laboratory, Japan · Decision date Oct 6, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for TSK OptiXion, a traditional 510(k) submitted by Tsk Laboratory, Japan, under 510(k) number K262516. The decision date is 2026-10-06; the application was received 07/21/2026. The device is listed under the classification name Ophthalmic Needle, regulation number 880.5570, with classification product code QYM and subsequent product codes FMI and QNS. The regulation medical specialty and review panel are both General Hospital.
SESE indicates clearance to market as substantially equivalent to a predicate device; it is not premarket approval of a new device. The record shows the review was not conducted by a third party, the product is not a combination product, and no predetermined change control plan was authorized. The public record does not identify the predicate device, the specific components or changes assessed, or the basis for the equivalence determination, so those details remain unknown from this source.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General Hospital
- Decision date
- Oct 6, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262516
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Tsk Laboratory, Japan
- Product code
- QYM
- Decision code
- SESE
- Decision date
- Oct 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Ophthalmic Needle.
- Applicant
- Tsk Laboratory, Japan
- Product code
- QYM
- FDA device class
- 2
FDA decision timeline
K262516 received
Application receipt date recorded by FDA.
K262516 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Tsk Laboratory, Japan
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Tochigi-Ken
Sources and methodology
- Original FDA record: K262516
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records